CMTM6 and CMTM7: New leads for PD-L1 regulation in breast cancer cells undergoing EMT

Malina Xiao, Caroline Duhem, Anwar Chammout, Guy Berchem, Bassam Janji*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Programmed death-ligand 1 (PD-L1) expression has long been used as a biomarker to stratify patients with cancer who will benefit from anti-PD-1/PD-L1 immunotherapy. However, the use of PD-L1 as a biomarker to guide treatment decisions has recently been called into question due to its dynamic and heterogeneous expression within each tumor and among different tumors as well as during tumor cell plasticity. Therefore, understanding the molecular basis of PD-L1 expression would enable delineating its value as a reliable biomarker in the clinic. Here, we provide our perspective on the involvement of CMTM6 and CMTM7 as new lead candidates for the regulation of PD-L1 in breast tumors undergoing an epithelial to mesenchymal transition.

Original languageEnglish
Pages (from-to)1025-1031
Number of pages7
JournalJournal of Cellular Biochemistry
Volume123
Issue number6
Early online date16 May 2022
DOIs
Publication statusPublished - Jun 2022

Keywords

  • breast cancer
  • CMTM6
  • epithelial-to-mesenchymal transition
  • immuno-oncology
  • immunotherapy
  • PD-1
  • programmed death-ligand 1 (PD-L1)

Fingerprint

Dive into the research topics of 'CMTM6 and CMTM7: New leads for PD-L1 regulation in breast cancer cells undergoing EMT'. Together they form a unique fingerprint.

Cite this